looksthread
Pharmaceutical
PharmaceuticalBody Prescription

GH Secretagogues

Also known as CJC-1295, ipamorelin, sermorelin, tesamorelin, GHRP-6

Peptides that ask your pituitary to release its own growth hormone rather than injecting hormone directly. Only a couple have genuine approval.

Evidence
Weak
Typical cost
$60 – $400
Permanence
Ongoing use
Timeline
Body composition shifts, if any, over 3–6 months.

Tesamorelin is expensive and prescription-only. Grey-market blends run $60–200/month with unverifiable contents.

How it works

GHRH analogues (sermorelin, tesamorelin, CJC-1295) and ghrelin-receptor agonists (ipamorelin, GHRP-2/6) stimulate pulsatile GH release from the pituitary. Because release stays pulsatile and subject to somatostatin feedback, peak IGF-1 is lower than with injected GH — which is the safety argument for them, and also the reason effects are smaller.

How it's used

Tesamorelin is approved for HIV-associated lipodystrophy and sermorelin has had diagnostic use; the rest are unapproved and sold as research chemicals. Blends like "CJC-1295/ipamorelin" have no approved protocol and no quality control. All are prohibited in tested sport. If you are chasing body composition, training and protein intake are doing more work than this ever will.

Trade-offs

In favour

  • More physiological release pattern than injected GH
  • Tesamorelin has real approval and trial data for visceral fat
  • Lower acromegaly risk than supraphysiological GH

Against

  • Most are unapproved and unregulated
  • Effects are modest and reverse on stopping
  • Expensive for the return
  • Banned in tested sport

Risks and side effects

Read before deciding
  • Unregulated sourcing and counterfeit product
  • Water retention, joint aches, tingling and numbness
  • Raised blood glucose and insulin resistance
  • Ghrelin agonists sharply increase appetite
  • Prolactin and cortisol elevation with older GHRPs
  • Any sustained IGF-1 elevation carries the same theoretical proliferation concerns as GH

How good is the evidence?

Weak
Limited or conflicting evidence.

Tesamorelin has good trial evidence in its licensed indication. The popular grey-market blends have essentially no controlled human data for cosmetic use.

Sources

Sources point to guideline bodies and literature searches rather than single papers, so they stay accurate as the evidence moves.

More in Pharmaceutical